New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
November 28, 2018 - The FDA announced the approval of Catalyst Pharmaceutical’s Firdapse (amifampridine), for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.
Download PDF
Return to publications
